family with sequence similarity 66 member CGenealiases: []
Q-omics provides the consensus-scored FAM66C profile across patient tissues and cancer cell-line models. FAM66C expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM66C is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, FAM66C RNA expression shows 19,878 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where FAM66C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM66C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM66C survival associations across molecular data types. FAM66C RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM66C RNA expression–survival associations across cancer types. High FAM66C expression shows unfavorable associations in KIRP, COAD, UVM and DLBC, but favorable associations in SKCM and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM66C RNA expression.
This table summarizes FAM66C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM66C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM66C shows lower tumor expression in KICH, LUAD, UCEC, BRCA, LUSC and STAD. The KICH box plot shows higher FAM66C RNA expression in normal versus tumor tissue (log2 FC = −1.166, t-test p < 0.001).
This table shows molecular features associated with FAM66C in patient tissues and cancer cell lines. In patient samples, FAM66C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
